BioSpace News Archive

TriSalus Life Sciences® Inc. announced that it has commenced an exchange offer and consent solicitation relating to its warrants identified in the Prospectus/Offer to Exchange.

BeiGene, Ltd., a global oncology company, announced the presentation of new analyses for BRUKINSA® at the American Society of Clinical Oncology Annual Meeting in Chicago, May 31 - June 4, 2024.

Exact Sciences Corp. will present 10 abstracts highlighting the breadth and depth of the company’s screening and diagnostic portfolio at the American Society of Clinical Oncology® Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, Ill.

Bio-Path Holdings, Inc. announced an upcoming poster presentation at the 2024 European Hematology Association Congress, taking place June 13-16, 2024 in Madrid, Spain.

BioLineRx Ltd. announced that an abstract including new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination clinical trial was accepted for presentation at the 2024 American Society of Clinical Oncology Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois.

Oncolytics Biotech® Inc., a leading clinical-stage company specializing in immunotherapy for oncology, presented two abstracts at the 2024 American Society of Clinical Oncology Annual Meeting.

Verastem Oncology announced that it has initiated the rolling submission of a New Drug Application to the U.S. Food and Drug Administration seeking accelerated approval of the combination of avutometinib, a RAF/MEK clamp, and defactinib, a selective FAK inhibitor, for adult patients with recurrent KRAS mutant low-grade serous ovarian cancer, who received at least one prior systemic therapy.

Genelux Corporation announced the pricing of an underwritten offering of 6,875,000 shares of its common stock and accompanying warrants to purchase 6,875,000 shares of its common stock at a combined offering price of $4.00 per share and accompanying warrant, in each case before underwriting discounts and commissions.

Shanghai Juncell Therapeutics Co., Ltd., a clinical-stage biotech developing innovative Tumor-Infiltrating Lymphocyte therapies for cancers, announced latest clinical research results on GC203.

Rakuten Medical, Inc. announced the updated safety and efficacy findings from an interim evaluation of an open-label Phase 1b/2 study of photoimmunotherapy using ASP-1929 in combination with anti-PD-1 for recurrent and/or metastatic head and neck squamous cell carcinoma.